TMC-Allseas Deal Advances Commercial Plans, But Regulatory and Financing Hurdles Remain

What happened

TMC and Allseas signed a commercial agreement to develop a 3.0 Mtpa offshore nodule collection system, targeting commissioning in Q4 2027 subject to permits, and with subcontract awards expected by end of Q3 2026. The deal provides a concrete timeline and improves the credibility of TMC's seabed-to-shore supply chain narrative, but the company remains pre-revenue and faces a lengthy NOAA permitting process with no statutory deadlines. The agreement also embeds financing mechanics that could increase dilution: Allseas settlement includes ~7.4 million shares and additional cash payments due 'in any event.' Meanwhile, TMC's Q1 2026 cash of $119.7M and ~$164M in current liquidity provide runway, but operating expenses are stepping up as EIS and industrialization work ramps. The stock at $5.70 still prices in a smooth regulatory path that overlooks the risk of timeline slippage, expanding EIS scope, and the unresolved U.S. processing requirement under DSHMRA.

Implication

While the commercial agreement with Allseas provides tangible near-term milestones (subcontract awards by Q3 2026) and improves operational credibility, it does not de-risk the regulatory pathway—NOAA certification and EIS completion remain gating factors with no statutory deadlines. The deal's financing structure, including share issuance and payable costs regardless of permit progress, means any delays directly translate into dilution, not just schedule slip. The unresolved DSHMRA U.S.-processing requirement (or need for a waiver) adds another layer of execution risk that the market may be underweighting. With a current liquidity of ~$164M and negative operating cash flow, TMC will likely need additional capital before revenue if the permitting timeline extends beyond management's expectation of Q1 2027. Investors should wait for observable regulatory progress—specifically, NOAA certification completion and a Notice of Intent to Prepare an EIS—before adding exposure, as the stock offers limited compensation for the remaining uncertainties.

Thesis delta

The Allseas agreement shifts the narrative from pure permitting optionality to an industrial execution track with monitorable milestones, but it also introduces concrete deadlines that, if missed, will accelerate dilution. The core thesis remains that TMC's stock prices a smooth regulatory outcome that is not assured, and the agreement does not reduce the dominant risk of timeline slippage and financing overhang. Consequently, the thesis shifts slightly: we now have a clearer event to track (subcontract awards by Q3 2026), but the overall assessment remains cautious, with downside still outweighing upside over the next 6–12 months.